XOMA Royalty Corp (XOMAP)Healthcare | Biotechnology | EmeryVille, United States |
USD
|
Hot Take ↕ | Aug. 22, 2026, 6:30 a.m. UTC
The immediate outlook is flat due to a complete lack of price history; the security has too little trading data to assess momentum or technical setups, leaving the short-term view neutral despite the recent acquisition news. On a longer horizon, the business faces a significant headwind: while the company boasts exceptional profitability margins and a massive return on equity, it is currently shrinking its top line by nearly 23%. This revenue contraction suggests the royalty model may be struggling to scale or maintain volume, which caps the long-term investment thesis at neutral rather than a buy. Finally, the dividend offers an attractive 8.6% yield, but given the negative free cash flow and the recent tender offer activity, this payout appears unsustainable and likely represents a return of capital or NAV erosion rather than a reliable income stream. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Ex Dividend Date | 2026-07-02 |
| Last Dividend Date | 2026-07-02 |
| Debt to Equity Ratio | 110.485 |
| Revenue per Share | 4.025 |
| Trailing P/E | 24.95 |
| Beta | 0.87 |
| Profit Margins | 69.63% |
| Website | https://www.xoma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.029902935 |
| Address1 | 2,200 Powell Street |
| Address2 | Suite 310 |
| All Time High | 30.0 |
| All Time Low | 21.4 |
| Ask | 26.41 |
| Ask Size | 100 |
| Average Daily Volume10 Day | 915 |
| Average Volume | 2,858 |
| Average Volume10Days | 915 |
| Beta | 0.865 |
| Bid | 25.17 |
| Bid Size | 1,000 |
| Book Value | 7.794 |
| City | EmeryVille |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Currency | USD |
| Current Price | 24.97 |
| Current Ratio | 3.59 |
| Date Short Interest | 1,782,777,600 |
| Day High | 24.97 |
| Day Low | 24.97 |
| Debt To Equity | 110.485 |
| Dividend Rate | 2.16 |
| Dividend Yield | 0.0863 |
| Earnings Growth | 2.079 |
| Earnings Quarterly Growth | 0.886 |
| Ebitda | 8,295,000 |
| Ebitda Margins | 0.17084 |
| Enterprise To Ebitda | 44.844 |
| Enterprise To Revenue | 7.661 |
| Enterprise Value | 371,980,928 |
| Ex Dividend Date | 1,782,950,400 |
| Exchange | NGM |
| Exchange Timezone Name | UTC |
| Fifty Day Average | 25.314669 |
| Fifty Two Week High | 30.0 |
| Fifty Two Week Low | 24.93 |
| Financial Currency | USD |
| First Trade Date Epoch Utc | 1,784,035,800 |
| Five Year Avg Dividend Yield | 8.23 |
| Float Shares | 4,798,073 |
| Free Cashflow | -13,069,500 |
| Full Time Employees | 14 |
| Fullday Price | 24.97 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.99036 |
| Gross Profits | 48,087,000 |
| Held Percent Insiders | 0.0 |
| Held Percent Institutions | 0.01016 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investors.xoma.com/ |
| Last Dividend Date | 1,782,950,400 |
| Last Dividend Value | 0.53906 |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California. As of July 14, 2026, XOMA Royalty Corporation operates as a subsidiary of Ligand Pharmaceuticals Incorporated. |
| Long Name | XOMA Royalty Corp |
| Max Age | 86,400 |
| Message Board Id | finmb_36769 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 19,932,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Open | 24.985 |
| Operating Cashflow | 6,794,000 |
| Operating Margins | -0.03897 |
| Phone | 510 204 7200 |
| Previous Close | 24.97 |
| Price Hint | 2 |
| Price To Book | 3.2037463 |
| Profit Margins | 0.69632006 |
| Quick Ratio | 3.308 |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Regular Market Day High | 24.97 |
| Regular Market Day Low | 24.97 |
| Regular Market Open | 24.985 |
| Regular Market Previous Close | 24.97 |
| Regular Market Volume | 3,716 |
| Return On Assets | 0.01283 |
| Return On Equity | 0.34234002 |
| Revenue Growth | -0.226 |
| Revenue Per Share | 4.025 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Short | 556 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 84 |
| Short Name | XOMA Royalty Corporation - 8.62 |
| Short Ratio | 0.1 |
| State | CA |
| Symbol | XOMAP |
| Time Zone Full Name | America/New_York |
| Time Zone Short Name | EDT |
| Total Cash | 86,094,000 |
| Total Cash Per Share | 6.865 |
| Total Debt | 124,732,000 |
| Total Revenue | 48,555,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 1.001 |
| Trailing P E | 24.945053 |
| Trailing Peg Ratio | None |
| Two Hundred Day Average | 25.997128 |
| Underlying Symbol | XOMAP |
| Uuid | c0909df4-4627-31c7-aa79-3a0174c69c16 |
| Volume | 3,716 |
| Website | https://www.xoma.com |
| Zip | 94,608 |